A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab

[1]  Andrew P. Stubbs,et al.  Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. , 2016, Cancer research.

[2]  R. Stupp,et al.  LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL , 2015 .

[3]  Kirsten L. Greene,et al.  miRNA Expression Analyses in Prostate Cancer Clinical Tissues. , 2015, Journal of visualized experiments : JoVE.

[4]  Timothy C Ryken,et al.  Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.

[5]  R. Bourgon,et al.  Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Rai,et al.  Assay Reproducibility in Clinical Studies of Plasma miRNA , 2015, PloS one.

[7]  P. Wen,et al.  Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies , 2015, Cancer.

[8]  David Westhead,et al.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature , 2015, Molecular oncology.

[9]  Anna Luisa Di Stefano,et al.  VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab , 2015, Journal of Neuro-Oncology.

[10]  B. Yan,et al.  miRNA-directed regulation of VEGF in tilapia under hypoxia condition. , 2014, Biochemical and biophysical research communications.

[11]  T. Jiang,et al.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. , 2014, Neuro-oncology.

[12]  C. Brennan,et al.  Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma , 2014, Clinical Cancer Research.

[13]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[14]  Eugene Berezikov,et al.  Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma , 2014, Oncotarget.

[15]  R. Vernhout,et al.  GE-10IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB. , 2014 .

[16]  Jakob Nikolas Kather,et al.  Angiopoietin-1 is regulated by miR-204 and contributes to corneal neovascularization in KLEIP-deficient mice. , 2014, Investigative ophthalmology & visual science.

[17]  M. Sanson,et al.  Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. , 2014, Neuro-oncology.

[18]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[19]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[20]  Catarina Osório,et al.  miR-363-5p regulates endothelial cell properties and their communication with hematopoietic precursor cells , 2013, Journal of Hematology & Oncology.

[21]  J. D. de Groot,et al.  Acquired Resistance to Anti-VEGF Therapy in Glioblastoma Is Associated with a Mesenchymal Transition , 2013, Clinical Cancer Research.

[22]  Martin Reczko,et al.  DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows , 2013, Nucleic Acids Res..

[23]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[24]  D. Oh,et al.  Sungsanpin, a lasso peptide from a deep-sea streptomycete. , 2013, Journal of natural products.

[25]  Y. Jeng,et al.  Amendment history : Corrigendum ( January 2017 ) Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility , 2018 .

[26]  A. Pertsemlidis,et al.  Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization , 2012, PloS one.

[27]  T. Afonyushkin,et al.  Permissive role of miR-663 in induction of VEGF and activation of the ATF4 branch of unfolded protein response in endothelial cells by oxidized phospholipids. , 2012, Atherosclerosis.

[28]  J. Heymach,et al.  Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.

[29]  Crispin J. Miller,et al.  Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation , 2012, British Journal of Cancer.

[30]  Martin Reczko,et al.  DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways , 2012, Nucleic Acids Res..

[31]  M. J. van den Bent,et al.  Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material , 2011, British Journal of Cancer.

[32]  M. Kutryk,et al.  Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease. , 2011, Biochemical and biophysical research communications.

[33]  J. Goeman.  L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.

[34]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[35]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[36]  C. Thiele,et al.  Brain-Derived Neurotrophic Factor Activation of TrkB Induces Vascular Endothelial Growth Factor Expression via Hypoxia-Inducible Factor-1α in Neuroblastoma Cells , 2006 .

[37]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[38]  D. Yamashiro,et al.  VEGF blocking therapy in the treatment of cancer , 2003, Expert opinion on biological therapy.

[39]  Y. Jeng,et al.  Angiopoietin-like protein 1 suppresses SLUG to inhibit cancer cell motility. , 2017, The Journal of clinical investigation.

[40]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[41]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .